Pharmacology and clinical evaluation of pralatrexate for treatment of peripheral T-cell lymphomaDAI Yi97-100
Problems and strategies of the causality assessment of adverse events in the phase I clinical trialsLI Tao, LU Yan101-105
Analyses of GAP on-site inspection and suggestions on GAP plant constructionXIAO Jiang-yi, WANG Wen-quan106-109,128
Tolerance and safety of buagafuran in Chinese healthy volunteersWANG Xue-qin, ZHAO Zhen-guo, HAN Bao-jie, ZHANG Hong-yan, YIN Da-li, FU Yi, LI Ling-zhi, HUANG Lan, MI Wei-feng, LI Zi-meng, WU Cong-li, GAO Lian-sheng110-114
Inhibitory effect of diacetyldianhydrogalactitol on transplanted hepatocarcinoma 22 growth and angiogenesis in miceLIU Jing-tao, GUO Wei, XU Bo, TONG Kan, ZHOU Ying, CUI Jing-rong115-119
Advances in the research for pharmacological activities and analysis methods of resveratrol derivatives and analoguesMA Ning, WANG Jian-fen, XU Fang, WEI Dan-dan, LI Juan, XIANG Da-xiong120-128
Abroad and home production situations, R&D progress and market analysis of immunosuppressive agents from microorganismsGU Jue-fen, WANG Wei129-136
Recent advance in the research of class B metallo-β-lactamase inhibitorsSHEN Bing-zheng, ZHENG Heng, NI Meng-xiang, GU Jue-fen143-147
A phase Ⅰ clinical trial of ursolic acid nanoliposome for evaluating its single-dose tolerance and safetyZHAO Cui-cui, QIAN Zheng-zi, WANG Hua-qing, SONG Zheng, MENG Xiang-rui, ZHAO Jing, YAN Zhao, HAO Xi-shan148-151